Get started
Work

83RO Trastuzumab pamirtecan (T-Pam/DB-1303/BNT323) in patients (pts) with previously treated, HER2-expressing, advanced endometrial cancer (EC): Overall survival (OS) and efficacy in pt subgroups of a phase II dose-expansion cohort

Year: 2026
Type: article
Abstract: T-Pam, a HER2-targeted ADC, has demonstrated antitumor activity in pts with pretreated, advanced, HER2-expressing recurrent EC. Encouraging response rates were observed across all HER2 expression levels (IHC 1+, 2+ or 3+) with the highest response in IHC3+ (confirmed ORR: ∼73% per local testing). Here, we report data from key subgroups and OS from this cohort.
Source: ESMO Open
DOI: 10.1016/j.esmoop.2026.108100
Authors: K.N. Moore, X. Wu, V. Makker, W. Growdon, F. Musa, D.L. Richardson, O. Yeku, H. Zheng, M. Carney, L. Wang, M. Ni, H. Yu, J. Liu, H. Lou, Z. Guo, J. Lee, N. Lang, M. Wenger, H. Mu, B. Pothuri
Institutions: University of Nebraska Medical Center, Fudan University Shanghai Cancer Center, Memorial Sloan Kettering Cancer Center, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University, OU Health Stephenson Cancer Center, University of Oklahoma, Harvard University, Massachusetts General Hospital, Peking University Cancer Hospital, Hawaii Pacific Health, University of Hawaii Cancer Center, Zhengzhou University, Henan Cancer Hospital, Shanghai Medical College of Fudan University, Fudan University, Shandong Tumor Hospital, Shandong First Medical University, Sun Yat-sen University Cancer Center, Zhejiang Cancer Hospital, University of Chinese Academy of Sciences, BioNTech (United States), BioNTech (Germany), Duality Biotherapeutics, Inc. (China)
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,910
OpenAlex ID: W7167053280
FWCI:
Cites:
Cited by:
Related to: